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Organoiron chemistryWe report the synthesis and biological evaluation of three analogues of the natural product (+)-grandi-
ﬂoracin (+)-1. All three analogues exhibit enhanced antiproliferative activity against PANC-1 and
HT-29 cells compared to the natural product. The retention of activity in an analogue lacking the enone
functional group, 9, implies this structural element is not an essential part of the (+)-grandiﬂoracin
pharmacophore.
 2014 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/3.0/).Pancreatic cancer has one of the lowest 5-year survival rates of
any cancer, at just 3–5%; in contrast to many other cancers, this ﬁg-
ure has not improved in the last 40 years.1 The reasons for this
poor survival rate are numerous. It is one of the most aggressive
of all human malignancies and as it is often asymptomatic in its
early stages, the vast majority of patients already have metastatic
tumours upon presentation.1 Therefore, surgical resection (the
only effective treatment modality) is not appropriate in most
cases; those patients who do undergo surgery have a 5-year sur-
vival rate which is improved only to 20%.1 Furthermore, there is
a lack of effective chemotherapies for pancreatic cancer, with
anti-cancer agents that are effective against other tumour types
having negligible effect.2 Gemcitabine is typically administered in
palliative chemotherapy for pancreatic cancer, but the survival
beneﬁt it imparts is marginal.2,3 On the basis of the above, it can
be stated that an effective pancreatic cancer therapy constitutes
a pressing unmet medical need. Accordingly, much effort is cur-
rently being directed towards the development of second-line
therapies, adjuvant therapies and combination therapies. Recently,
the combination of gemcitabine and erlotinib has been shown to
lead to an enhanced 1-year survival rate of 23% as opposed to17% for gemcitabine alone.4 Nevertheless, it is clear that a major
breakthrough in the treatment of pancreatic cancer will likely
require the use of wholly new therapeutic strategies exploiting
emerging targets.5
In this context, the ‘anti-austerity’ strategy ﬁrst described by
Esumi and co-workers6 in 2000 is particularly promising. Pancre-
atic tumours are generally hypovascular, with the consequence
that the tumour microenvironment is hypoxic and comparatively
nutrient-deprived in comparison with normal tissues. Despite this,
pancreatic cancer cells are nevertheless able to proliferate rapidly
under these austere conditions. Their ability to tolerate nutrient
deprivation is far greater than that of normal tissues and indeed
of other cancer cell lines.6 An anti-austerity agent is deﬁned as a
drug that is able to remove the ability of cancer cells to survive
under conditions of nutrient starvation, whilst cells with adequate
nutrition remain unaffected.6 Such a drug would represent a novel
means of selectively targeting pancreatic tumours in vivo. It should
be noted that such behaviour would be in contrast to that of most
chemotherapeutic agents, whose efﬁcacy is typically reduced
under conditions of nutrient deprivation.7 Esumi’s initial study
identiﬁed two agents, troglitazone and LY294002, that possess
such anti-austerity activity in PANC-1 cells. In the subsequent per-
iod, many more anti-austerity agents have been identiﬁed and the
ﬁeld has recently been reviewed.8 Most anti-austerity agents
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on plant extracts enabled by the assay reported by Esumi. To date,
three agents identiﬁed by this method have been evaluated in vivo
as well as in vitro—the known anthelminthic, pyrvinium pamoate9
and the natural products kigamicin D,7,10 and ()-arctigenin;11 all
were found to suppress tumour growth in mouse models. The full
details of the mode(s) of action of these anti-austerity agents have
not yet been elucidated, but it has recently been disclosed that pyr-
vinium pamoate inhibits the NADH-fumarate reductase system.12
This is a mitochondrial energy-generating system that shows
increased activity in PANC-1 cells cultured under austere condi-
tions and is also employed by parasitic helminths for survival in
the hypoxic conditions of their hosts’ intestines.13
The therapeutic promise of anti-austerity agents has attracted
the attention of synthetic chemists, with several reports of synthe-
ses of these agents and analogues. Several total syntheses of the
anti-austerity agent (+)-angelmarin14 have been reported (both
in enantiopure form15,16 and as the racemate17,18) and Coster has
reported the synthesis of a library of angelmarin analogues, one
of which exhibited enhanced potency with respect to the natural
product.19 Additionally, Carrico–Moniz has reported a novel
geranylgeranylated hydroxycoumarin having some structural
homology with angelmarin, that displays anti-austerity activity
against PANC-1 cells also.20 No total syntheses of the kigamicins
have been disclosed to date, but Whatmore, Shipman and co-
workers have synthesised and evaluated truncated analogues in
an attempt to establish the kigamycin pharmacophore; they report
that 7-phenyltetrahydroxanthone displays anti-austerity activity,
being 100-fold less potent than kigamicin C.21 Elsewhere, several
total syntheses have been reported of ()-arctigenin22–25 (and also
of (±)-arctigenin26 and (+)-arctigenin,27 which is also a natural
product,28 although it has only very weak anti-austerity activ-
ity29,30). It should be noted that in fact ()-arctigenin is readily
accessible from natural sources.31,32 Signiﬁcantly, a recent report
from Toyooka, Tezuka and co-workers29 describes two analogues
with enhanced potency compared to ()-arctigenin.
There has been a high and sustained level of interest in anti-
austerity agents in recent years; a key report, from Awale et al.33
disclosed that (+)-grandiﬂoracin, (+)-1, isolated from Uvaria dac,
is a potent antiausterity agent in four pancreatic cancer cell lines:
PANC-1 (PC50, 14.5 lM), PSN-1 (PC50, 32.6 lM), MIA PaCa-2 (PC50,
17.5 lM), and KLM-1 (PC50, 32.7 lM). Awale’s report also repre-
sented the ﬁrst time that the (+)-enantiomer of 1 had been isolated
from nature (the antipodal ()-1 had been isolated previously from
several other species of the same genus,34–37 but its antiprolifera-
tive activity has not been evaluated). Most recently, a 2014 report
from Awale details studies on the mode of action of (+)-grandiﬂor-
acin, which reveal that it induces the autophagic cell death of
PANC-1 cells under nutrient deprivation.38 Furthermore, (+)-gran-
diﬂoracin was found to inhibit strongly both the phosphorylation
of Akt at Ser473 and the phosphorylation of mTOR at Ser2448.38
In most pancreatic cancer cell lines the serine/threonine kinase
Akt/mTOR pathway is constitutively activated and under condi-
tions of nutrient deprivation, Akt has been shown to be
overexpressed.
We recently reported39 the ﬁrst enantioselective total synthesis
of (+)-1, employing a starting material 2 whose chemistry we haveOH
COOH OH
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Scheme 1. Grandiﬂoracin may beextensively developed.40–49 Homochiral diol acid 2 is derived from
a dearomatising biooxidation of benzoic acid 3 (Scheme 1). A
synthesis of (±)-1 has also been reported.50 The small quantities
of (+)-1 available from the natural source (100 g of plant material
yielded 7 mg of (+)-1) have precluded analogue semisynthesis to
date. Our route is sufﬁciently concise to provide larger quantities
of (+)-1 and also sufﬁciently ﬂexible to allow analogue total
synthesis. In this Letter we describe the synthesis of analogues of
(+)-1 (by both semisynthesis and total synthesis) and their evalu-
ation as anti-austerity agents.
In the ﬁrst instance we targeted the ester motifs of (+)-grandi-
ﬂoracin as sites for diversiﬁcation. In our original synthesis of
(+)-1,39 the benzoate group was introduced selectively on the
primary alcohol in triol 4, which was accessed in three steps from
2 (Scheme 2). In the present case, treatment of 4 with other aroyl
chlorides gave para-substituted benzoates 5a and 5b in yields
comparable to that obtained with benzoyl chloride. It was found
that pre-mixing the aroyl chloride and 2,4,6-collidine minimisedOH
O
BzO
H O
OH
H
OBz
COOH
(+)-1
accessed from benzoic acid.
(OC) 3Fe
OH
OH
O
O
OMe
Figure 2. ORTEP diagram of 5b showing ellipsoids at 30% probability. H atoms are
shown as spheres of arbitrary radius. CCDC #958601.
OH
O
BzO
H O
OH
H
OBz
(+)-1
OH
O
BzO
H O
OH
H
OBz
9
H2, Pd / C
MeOH, r.t., 16 h, 83%
Scheme 4. Hydrogenation of (+)-grandiﬂoracin.
Table 1
Antiproliferative activity of (+)-grandiﬂoracin and analogues in PANC-1 cells
Test agent IC50 (lM) mean (SE)
0.5% Serum 10% Serum
(+)-1 >500 123 (12.5)
8a 77 (1.4) 84 (7.1)
8b 52 (0.7) 78 (9.2)
9 86 (17.7) 81 (6.5)
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Scheme 5. Hypothetical Michael addition of a biological nucleophile (e.g., thiol) to
(+)-1.
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were characterised by X-ray crystallography (Figs. 1 and 2).
The secondary alcohols in esters 5a and 5b were oxidised to
ketones 6a and 6b with manganese dioxide. Cyclohexadienones
are known to undergo spontaneous Diels–Alder dimerisation, but
when complexed as g4 ligands to iron(0), this process is suppressed
and 6a/6bwere found to be stable and characterisable. Upon treat-
ment with cerium ammonium nitrate, 6a and 6b underwent
smooth decomplexation to free cyclohexadienones 7a and 7b.
These were not isolated, but instead underwent spontaneous
dimerisation to give grandiﬂoracin analogues 8a and 8b
(Scheme 3).51
A second approach to analogue preparation was undertaken,
this time effecting semisynthetic functional group deletion by
means of reduction of (+)-1 to give tetrahydrograndiﬂoracin 9
(Scheme 4). We envisaged that this analogue would provide a
means of assessing the importance or otherwise of the (nonaro-
matic) unsaturation in (+)-1 in terms of its anti-austerity activity.
With three novel analogues of (+)-grandiﬂoracin in hand, we
undertook the evaluation of their anti-austerity properties in a
variety of cell lines. In the ﬁrst instance, we determined the anti-
proliferative effects of (+)-1, 8a, 8b and 9 in the PANC-1 pancreatic(OC)3Fe
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Scheme 3. Synthesis of grandiﬂocancer cell line. Each agent was evaluated both under compara-
tively nutrient rich (10% fetal bovine serum) and nutrient deprived
(0.5% fetal bovine serum) culture conditions. Cells were exposed to
the test agent for 72 h and gemcitabine and 5-ﬂuorouracil were
employed as positive controls (see Supplementary information).
The cell culture conditions were not identical to those employed
by Awale et al.33 and as such the data presented here are not
directly comparable with those in the previous Letter. Rather, we
adopted conditions of less extreme nutrient deprivation (see
Supplementary information) analogous to those that are likely
present in the actual tumour microenvironment, fully expecting
that prospective anti-austerity agents might be less potent under
such conditions. The calculated IC50 values are shown in Table 1.
The data are noteworthy in several respects. Contrary to our
expectations, (+)-1 proved inactive up to 500 lM in 0.5% serum,
yet exhibited an IC50 of 123 lM in 10% serum. The anomalous nat-(OC)3Fe
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Figure 3. Molecular modelling: (a) minimised structure of (+)-1; (b) schematic representation of the potential pharmacophore of (+)-1; (c) minimised structure of 9; (d)
schematic representation of the potential pharmacophore of 9. (A = hydrogen bond acceptor, D = hydrogen bond donor, H = hydrophobic region, R = aromatic ring).
Table 2
Antiproliferative activity of (+)-grandiﬂoracin and analogues in HT-29 cells
Test agent IC50 (lM) mean (SE)
0.5% Serum 10% Serum
(+)-1 >500 109 (2.4)
8a 18 (3.3) 39 (4.4)
8b 22 (1.8) 35 (3.3)
9 27 (2.2) 39 (5.6)
2818 M. Ali Khan et al. / Bioorg. Med. Chem. Lett. 24 (2014) 2815–2819ure of this result is underlined by the fact that analogues varying
only in the nature of the ester side chains, 8a and 8b, are active.
Indeed, they are more potent than (+)-1 under both cell culture
conditions. It is possible, however, that (+)-1, 8a and 8bmay in fact
be prodrugs, all affording the same tetraol upon the action of
intracellular esterases; the enhanced activity of 8a and 8b with
respect to (+)-1 may be due to differences in lipophilicity and cell
permeability. Arguably the most signiﬁcant result presented in
Table 1 is the increase in antiproliferative activity upon hydrogena-
tion of (+)-1 to 9. Inspection of the structure of (+)-1 had initially
led us to speculate that the enone motif might serve as a Michael
acceptor and that (+)-1 (or its metabolite) might exert its effects
by covalent modiﬁcation of its target(s) (Scheme 5).52 That tetrahy-
drograndiﬂoracin 9 retains its potency in the absence of the enone
leads us to conclude that in fact neither the enone motif, nor the
electron-rich alkene, are required for antiproliferative activity in
this cell line. Both (+)-1 and 9 were modelled using Maestro53
and it was determined that hydrogenation of (+)-1 to 9 induces
only very subtle conformational changes. The rigid nature of the
bicyclo[2.2.2]octene skeleton in the western hemisphere of (+)-1
means it has very limited scope to undergo conformational change
upon reduction to 9. The eastern hemisphere of (+)-1 is less
constrained, but even here the only appreciable change upon
reduction to 9 is in the relative positions of the two carbons that
have rehybridised from sp2 to sp3; more broadly other functional
groups do not move signiﬁcantly. Thus, all functionality which
might constitute part of the grandiﬂoracin pharmacophore is
highly conserved between the two structures. For example, in
(+)-1, the distance between two representative hydrogen bond
acceptors, the two ketone oxygens (labelled as A7 and A8 in
Fig. 3b), is 7.12 Å, and this distance is unchanged in 9. Similarly,
the distance between the two hydrogen bond donors, the tertiary
hydroxyl oxygens (labelled D9 and D10 in Fig. 3b) is 4.50 Å in
(+)-1 and 4.54 Å in 9.
We next sought to evaluate the effects of (+)-1, 8a, 8b and 9 on
other (non-pancreatic) tumour cell lines. IC50 values obtained for
these agents in HT-29 human colon cancer cells are shown in
Table 2. Three trends are evident in the data: (a) all three novel
analogues are more active than (+)-1, under both cell culture
conditions (as was the case for PANC-1 also). (b) All three novel
analogues are more active than in PANC-1 cells. (c) All three novel
analogues exhibited lower IC50 values under the comparatively
nutrient deprived conditions (0.5% serum), that is, an anti-austerity
effect. To our knowledge, this is the ﬁrst time such an anti-
austerity effect has been demonstrated for HT-29 cells.In summary, we have prepared three novel analogues of
(+)-grandiﬂoracin 1, all of which show enhanced antiproliferative
activity towards PANC-1 and HT-29 cells with respect to the parent
compound. We have also determined antiproliferative activities in
other cell lines. Current work in our laboratory is focused on the
preparation and evaluation of further analogues of (+)-1; results
will be reported in due course.
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